• Muhammad Asif, Muhammad Amir, Abrar Hussain, Niaz M Achakzai, Peter Natesan Pushparaj, and Mahmood Rasool.
• Department of Biotechnology, BUITEMS, Quetta, Pakistan.
• Medicine (Baltimore). 2022 Jul 1; 101 (26): e29660e29660.

AbstractSevere acute respiratory syndrome (SARS) caused by a novel coronavirus-2 (CoV-2), also known as COVID-19, has spread rapidly worldwide since it is recognized as a public health emergency and has now been declared a pandemic on March 11, 2020, by the World Health Organization. The genome of SARS-CoV-2 comprises a single-stranded positive-sense RNA approximately 27 to 30 kb in size. The virus is transmitted through droplets from humans to humans. Infection with the SARS virus varies from asymptomatic to lethal, such as fever, cough, sore throat, and headache, but in severe cases, pneumonia and acute respiratory distress syndrome. Recently, no specific and effective treatment has been recommended for patients infected with the SARS virus. However, several options can be investigated to control SARS-CoV-2 infection, including monoclonal antibodies, interferons, therapeutic vaccines, and molecular-based targeted drugs. In the current review, we focus on tyrosine kinase inhibitor management and their protective role in SARS-CoV-2 patients with chronic myelogenous leukemia.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

34 keywords...

hide…